Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yescarta (axicabtagene ciloleucel)
Pharma
Gilead's Kite exits China cell therapy JV with Fosun Pharma
Kite’s exit from the Fosun JV comes as CAR-T meds continue to navigate patient access and reimbursement dynamics in China.
Angus Liu
Sep 19, 2024 4:23pm
Gilead's at 'just the beginning' of cell therapy movement: exec
Feb 7, 2024 2:08pm
FDA wants classwide boxed warning on existing CAR-Ts
Jan 23, 2024 3:27am
CAR-T hype faces infrastructure reality check
Jan 15, 2024 3:00am
Cell therapy bigwigs endorse CAR-T in Nature Medicine article
Jan 9, 2024 5:00am
FDA probes CAR-T therapies' 'serious risk' of secondary cancer
Nov 28, 2023 1:16pm
